Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδT Cells in Hepatocellular Carcinoma
NCT04518774Phase 1Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic gamma-delta T cells in hepatocellular carcinoma (HCC), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Incidence of Adverse events (AEs) up to 48 weeks, Dose limited toxicity up to 48 weeks and 1 more. Status: unknown.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04518774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518774.